Please assess the completion status of the following clinical trial:

Trial Title: Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of Active (recurrent or persistent) subfoveal CNV lesions secondary to AMD in the study eye~* Prior Intravitreal Anti-VEGF injections~Key Exclusion Criteria:~* Significant subretinal hemorrhage~* Significant Scar and/or, fibrosis~* Suspected polypoidal choroidopathy, or pigment epithelial tears or rips~* Inadequate response to anti-VEGF therapy

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- NT-503-3 ECT implantation (Type: EXPERIMENTAL): None
- Eylea® injected intravitreally every 8 weeks (Type: ACTIVE_COMPARATOR): Eylea® injected intravitreally every 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).